Price
No data yet.
Social Signal Score
Analyst Ratings
49 analystsRevenue
$1.74B+135.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bernard J. Zovighian
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 16,000
- Beta
- 0.85
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 12.13
Financials
Revenue
$1.74B+135.5%Net Income
$241.90M+71.1%EBITDA
$519.50M+155.4%Free Cash Flow
$585.00M+271.2%EPS (diluted)
$0.42+90.9%Shares Outstanding (diluted)
577.60M-11.7%Operating Expenses
$840.10MCash & Debt
$4.25BReturn of Capital
$53.30MRevenue by Segment (annual)
$6.07BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.07B | $1.07B | $1.84 |
| 2024 | $5.44B | $4.17B | $6.98 |
| 2023 | $5.01B | $1.40B | $2.31 |
| 2022 | $5.38B | $1.52B | $2.46 |
| 2021 | $5.23B | $1.50B | $2.41 |
| 2020 | $4.39B | $823.40M | $1.32 |
| 2019 | $4.35B | $1.05B | $1.68 |
| 2018 | $3.72B | $722.20M | $1.15 |
| 2017 | $3.44B | $622.10M | $0.98 |
| 2016 | $2.96B | $569.50M | $0.89 |
| 2015 | $2.49B | $494.90M | $0.77 |
| 2014 | $2.32B | $811.10M | $1.27 |
| 2013 | $2.05B | $391.70M | $0.59 |
| 2012 | $1.90B | $293.20M | $0.43 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from EW's reported EPS growth of 11.8% a year over 13 years.
- EPS in 5 years
- $3.21
- Implied price
- $147.49
- Return from $85.15
- 11.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $73.33 — -13.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 32 | 39 | 46 | 53 | 60 |
|---|---|---|---|---|---|
| 1.8% | -5.5% | -1.7% | 1.6% | 4.6% | 7.2% |
| 6.8% | -0.8% | 3.2% | 6.6% | 9.7% | 12.4% |
| 11.8% | 3.8% | 8.0% | 11.6% | 14.8% | 17.7% |
| 16.8% | 8.4% | 12.8% | 16.6% | 20.0% | 23.0% |
| 21.8% | 13.1% | 17.6% | 21.6% | 25.1% | 28.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (16)
- Newsbusinesswire.com·1d ago·Neutral
Edwards Lifesciences to Host Investor Event in Conjunction With TCT IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relat…
View source ↗ - 4chan /biz/biz·8d ago·Neutral
>>62730530 >most of the oil is being routed around it now This is nonsense because Hootie and the blow fish are blocking bab el mandeb and hitting their EW pipeline facilities. This is all propaganda.
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
View source ↗ - News (RSS)seekingalpha·25d ago·Positive
Edwards Lifesciences praises CMS NCD on transcatheter aortic valve replacement
View source ↗ - Newsbusinesswire.com·25d ago·Positive
Edwards Lifesciences Comments on TAVR National Coverage Decision IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a mu…
View source ↗ - News (RSS)seekingalpha·27d ago·Neutral
Baron Asset Fund adds CBRS and EW; exits FICO and FND
View source ↗ - News (RSS)seekingalpha·29d ago·Neutral
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound
View source ↗ - News (Marketaux)seekingalpha.com·29d ago·Positive
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW)
View source ↗ - PodcastCompound And Friends·41d ago·Positive
is like Edwards and McGee stuff, but basically you would take the amount of the move that preceded it, and then on the other side, that's how far you should expect this to be able to keep running before it runs out of steam, so these are very bullish, this thing gapped up and never even looked back at that gap level, Michael, would you agree that's a pretty bullish formation in a chart, insanely, okay, management is now guiding to a fifth consecutive quarter of 10% or higher growth in usage, so
View source ↗ - News (RSS)zerohedge·44d ago·Neutral
…. Stout Stryker air artillery Mission Equipment Package). Dr. Smith outlined a layered approach beginning with Radio Frequency (RF) detection and Electronic Warfare (EW) at standoff ranges, then lasers for cost-effective engagement within line-of-sight, and kinetic interceptors when necessary. Speakers emphasized mobility and integrated C2 so that different defeat mechanisms can be applied as threats evolve, reflecting a pragmatic view that no single technology will defeat every class of drone. …
View source ↗ - Newszacks.com·46d ago·Neutral
Should You Hold Edwards Lifesciences Stock in Your Portfolio? EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
View source ↗ - Newszacks.com·52d ago·Positive
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation? Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
View source ↗ - Newszacks.com·53d ago·Positive
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
View source ↗ - News (RSS)yahoo·54d ago·Neutral
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
View source ↗ - News (Marketaux)seekingalpha.com·55d ago·Neutral
Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW) Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW)
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.74 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$0.78 vs $0.74beat
- Thu, Apr 23$0.78 vs $0.73beat
- Tue, Feb 10$0.58 vs $0.62miss
- Thu, Oct 30$0.67 vs $0.60beat
- Thu, Jul 24$0.67 vs $0.62beat
- Wed, Apr 23$0.64 vs $0.60beat
Estimates and results for EW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EW officers and directors.
- Bought
- —
- Sold
- $11.2m
0 trades
22 trades
- Lippis Daniel J.sold
- Dahl Andrew M.sold
- Bruls Annettesold
- Chopra Daveensold
- Chopra Daveensold
- Markowitz Waynesold
- Lippis Daniel J.sold
- Markowitz Waynesold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 30, 2025 (41d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$50,001 - $100,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 11, 2024 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Sep 19, 2024 (30d later)Sell$15,001 - $50,000
- Mike Kellyhouse · PA16 · disclosed Jun 14, 2024 (64d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (27d later)Buy$1,001 - $15,000
- John R. Curtishouse · UT03 · disclosed Dec 15, 2023 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.